TY - JOUR AU - Kravchun, N. A. AU - Khyzhnyak, Oksana PY - 2010/03/03 Y2 - 2024/03/28 TI - COMPARATIVE ANALYSIS OF GLIMEPIRIDE AND GLICLAZIDEMR USE IN TYPE 2 DIABETES MELLITUS TREATMENT JF - Problems of Endocrine Pathology JA - PEP VL - 31 IS - 1 SE - DO - 10.21856/j-PEP.2010.1.01 UR - https://www.jpep.endocrinology.org.ua/index.php/1/article/view/834 SP - 5-11 AB - <p>Results of the hypoglycemic therapeutic efficiency of Gliclazide and Glimepiride in patients with type 2 diabetes mellitus are represented in the open prospective study. Daily dose of GliclazideMR was 90 mg, and Glimepiride — 4 mg. It is evident that third-generation sulfonylurea — Glimepiride has more protective cardiovascular effects because it significantly decreases microalbumiurea. Moreover, it significantly improves postprandial and basal glycemia, and the HDLP cholesterol level in patients with 5-year DM2 history. As an anti-diabetic drug Glimepiride has some advantages with regard to a high risk of microvascular complications when the disease is in progress.</p> ER -